Trial Profile
A Phase 2 Study of Nivolumab and Ipilimumab in Advanced Leiomyosarcoma of the Uterus
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 05 Apr 2024
Price :
$35
*
At a glance
- Drugs Ipilimumab (Primary) ; Nivolumab (Primary)
- Indications Leiomyosarcoma; Uterine cancer
- Focus Therapeutic Use
- 04 May 2020 Status changed from completed to active, no longer recruiting.
- 21 Sep 2018 Status changed from suspended to completed.
- 11 Jul 2018 Status changed from recruiting to suspended.